Cite

HARVARD Citation

    Lam, C. et al. (2022). Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes. Circulation. 145 (8), p. . [Online]. 
  
Back to record